医薬品ドラッグデリバリー市場

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2021年11月

医薬品ドラッグデリバリー市場: 投与経路(経口、注射器、埋め込み型、シロップ、ゲル、肺、溶液、錠剤、注射器)、適用(癌、糖尿病)、使用施設(病院)、COVID-19の影響 – 2026年までの世界予測

Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact – Global Forecast to 2026

ページ数 556
図表数 690
種別 英文調査報告書

目次  お問合せ

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.
On the other hand, the risk of needlestick injuries and the increased pricing pressure is expected to limit the market growth to some extent in the coming years.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period
Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.
The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market
Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.
Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market
During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.
Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Pharmaceutical Drug Delivery Market
Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).
Research Coverage:
The report analyzes the pharmaceutical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as route of administration, application, facility of use, and region. The report also includes a product portfolio matrix of various pharmaceutical drug delivery available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product & service offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global pharmaceutical drug delivery market. The report analyzes this market by route of administration, application, and facility of use
• Solution Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global pharmaceutical drug delivery market
• Market Development: Comprehensive information on the lucrative emerging markets by route of administration, applications, and facility of use
• Market Diversification: Exhaustive information about new product enhancements, growing geographies, recent developments, and investments in the global pharmaceutical drug delivery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global pharmaceutical drug delivery market.


目次

1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION AND SCOPE 45
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.2.2 MARKETS COVERED 46
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION 46
1.2.3 YEARS CONSIDERED FOR THE STUDY 46
1.3 CURRENCY 47
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 47
1.4 STAKEHOLDERS 47
1.5 SUMMARY OF CHANGES 48

2 RESEARCH METHODOLOGY 49
2.1 RESEARCH APPROACH 49
FIGURE 2 RESEARCH DESIGN 49
2.1.1 SECONDARY RESEARCH 50
2.1.1.1 Key data from secondary sources 51
2.1.2 PRIMARY RESEARCH 52
FIGURE 3 PRIMARY SOURCES 52
2.1.2.1 Key data from primary sources 53
2.1.2.2 Insights from primary experts 54
2.1.2.3 Breakdown of primaries 54
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND PARTICIPANTS 54
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 55
2.2 MARKET SIZE ESTIMATION 55
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 56
FIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 56
FIGURE 8 PHARMACEUTICAL SALES APPROACH 57
FIGURE 9 TOP-DOWN APPROACH 57
FIGURE 10 CAGR PROJECTIONS 58
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR 59
2.3 DATA TRIANGULATION APPROACH 61
FIGURE 12 DATA TRIANGULATION METHODOLOGY 61

2.4 MARKET SHARE ESTIMATION 62
2.5 ASSUMPTIONS FOR THE STUDY 62
2.6 LIMITATIONS 62
2.6.1 METHODOLOGY-RELATED LIMITATIONS 62
2.7 RISK ASSESSMENT 63
TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL DRUG DELIVERY MARKET 63

3 EXECUTIVE SUMMARY 64
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD BILLION) 64
FIGURE 14 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) 65
FIGURE 15 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2021 VS. 2026 (USD BILLION) 66
FIGURE 16 GEOGRAPHIC ANALYSIS: PHARMACEUTICAL DRUG DELIVERY MARKET 67

4 PREMIUM INSIGHTS 69
4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW 69
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 69
4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY 70
FIGURE 18 THE HOSPITALS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET IN 2020 70
4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
FIGURE 19 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD 71
4.4 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (2019-2026) 72
FIGURE 20 NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL DRUG DELIVERY MARKET DURING FORECAST PERIOD 72
4.5 PHARMACEUTICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 73
FIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 73

5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
TABLE 3 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT ANALYSIS 74
5.2.1 MARKET DRIVERS 75
5.2.1.1 Rising prevalence of chronic diseases 75
5.2.1.2 Growth in the biologics market 76
TABLE 4 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020) 76
5.2.1.3 Technological advancements and new product launches 77
5.2.1.4 Increasing investments in pharmaceutical R&D 79
FIGURE 22 NUMBER OF PHARMACEUTICAL COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 79
FIGURE 23 GLOBAL PHARMA R&D SPENDING (2016–2020) 79
5.2.2 MARKET RESTRAINTS 80
5.2.2.1 Risk of needlestick injuries 80
5.2.3 MARKET OPPORTUNITIES 81
5.2.3.1 Self-administration and home care 81
5.2.3.2 Rising demand for biosimilars and biologics 81
5.2.4 MARKET CHALLENGES 82
5.2.4.1 Pricing pressure 82
5.3 COVID-19 IMPACT ON THE PHARMACEUTICAL DRUG DELIVERY MARKET 82
5.4 INDUSTRY TRENDS 84
5.4.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY TECHNOLOGIES 84
5.4.2 ADVANCEMENTS IN TECHNOLOGIES AND DESIGNS 84
5.5 REGULATORY ANALYSIS 85
TABLE 5 REGULATORY SCENARIO BY COUNTRY 85
5.6 PORTER’S FIVE FORCES ANALYSIS 88
TABLE 6 PORTER’S FIVE FORCES ANALYSIS (2020): PHARMACEUTICAL DRUG DELIVERY MARKET 88
5.6.1 THREAT FROM NEW ENTRANTS 88
5.6.2 THREAT FROM SUBSTITUTES 88
5.6.3 BARGAINING POWER OF SUPPLIERS 89
5.6.4 BARGAINING POWER OF BUYERS 89
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 89
5.7 VALUE CHAIN ANALYSIS 90
FIGURE 24 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 90
5.8 ECOSYSTEM MAPPING 91
FIGURE 25 ECOSYSTEM OF THE PHARMACEUTICAL DRUG DELIVERY MARKET 91
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 91
5.10 PATENT ANALYSIS 92
5.10.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 92
FIGURE 26 PATENT PUBLICATION, FILING, AND GRANT TRENDS (JANUARY 2011–OCTOBER 2021) 92
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 92
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 93
FIGURE 28 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021) 94
TABLE 7 SOME PATENTS/ PATENT APPLICATIONS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET, 2020-2021 94

6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 96
6.1 INTRODUCTION 97
TABLE 8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 97
6.2 ORAL DRUG DELIVERY 98
TABLE 9 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 98
TABLE 10 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 99
6.2.1 SOLID ORAL DRUGS 99
TABLE 11 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 100
TABLE 12 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 100
6.2.1.1 Tablets 101
6.2.1.1.1 The development of mini-tablets is a key trend in this market segment 101
TABLE 13 TABLETS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 102
6.2.1.2 Capsules 102
6.2.1.2.1 The easy absorption of drugs and decreased irritation in the GI tract drive the use of capsules 102
TABLE 14 CAPSULES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 103
6.2.1.3 Powders 103
6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms 103
TABLE 15 POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 104
6.2.1.4 Pills 105
6.2.1.4.1 The rising incidence of target ailments to propel the growth of the pills market 105
TABLE 16 PILLS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 105
6.2.2 LIQUID ORAL DRUGS 106
TABLE 17 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 106
TABLE 18 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 107
6.2.2.1 Syrups 107
6.2.2.1.1 Syrups can be easily administered to patients with swallowing difficulties 107
TABLE 19 ORAL SYRUPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 108
6.2.2.2 Solutions 108
6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients 108
TABLE 20 ORAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 109
6.2.3 SEMI SOLID ORAL DRUGS 109
TABLE 21 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 110
TABLE 22 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION) 110
6.2.3.1 Gels 111
6.2.3.1.1 Gels are used for controlled drug release 111
TABLE 23 ORAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 111
6.2.3.2 Emulsions 112
6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis 112
TABLE 24 ORAL EMULSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 112
6.2.3.3 Elixirs 113
6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances 113
TABLE 25 ORAL ELIXIRS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 113
6.3 INJECTABLE DRUG DELIVERY 114
TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 115
TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 115
6.3.1 CONVENTIONAL INJECTION DEVICES 116
TABLE 28 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 116
6.3.1.1 By material 117
TABLE 29 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 117
6.3.1.1.1 Glass Syringes 117
6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safest materials to store biological drugs 117
TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118
6.3.1.1.2 Plastic Syringes 118
6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts 118
TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 119
6.3.1.2 By product 119
TABLE 32 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 120
6.3.1.2.1 Fillable syringes 120
6.3.1.2.1.1 Ease of use and the variable dosing formulations of fillable syringes to drive the market growth 120
TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 121
6.3.1.2.2 Prefilled syringes 121
6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety 121
TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
6.3.1.3 By usability 123
TABLE 35 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 123
6.3.1.3.1 Reusable syringes 123
6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean 123
TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 124
6.3.1.3.2 Disposable syringes 124
6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience 124
TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 125
6.3.2 SELF-INJECTION DEVICES 125
TABLE 38 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 126
TABLE 39 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 127
6.3.2.1 Needle-free injectors 127
6.3.2.1.1 Needle-free injectors enable faster drug delivery and show better reproducibility as compared to invasive drug delivery systems 127
TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 128
6.3.2.2 Autoinjectors 128
6.3.2.2.1 Autoinjectors to provide improved patient satisfaction as compared to manual injections 128
TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 129
6.3.2.3 Pen injectors 129
6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week 129
TABLE 42 COMMERCIALLY AVAILABLE KEY PEN INJECTORS 130
TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 130
6.3.2.4 Wearable injectors 131
6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth 131
TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 131
6.3.3 OTHER INJECTOR DEVICES 132
TABLE 45 OTHER INJECTORS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 132
6.4 TOPICAL DRUG DELIVERY 133
TABLE 46 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 133
TABLE 47 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 134
6.4.1 LIQUID FORMULATIONS 134
TABLE 48 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 134
TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 135
6.4.1.1 Solutions 135
6.4.1.1.1 Ease of use and ready availability of the dosage form to support market growth 135
TABLE 50 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 136

6.4.1.2 Suspensions 136
6.4.1.2.1 Factors such as the high rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market 136
TABLE 51 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 137
6.4.2 SEMI SOLID FORMULATIONS 137
TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 138
TABLE 53 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 138
6.4.2.1 Creams 139
6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions 139
TABLE 54 TOPICAL CREAMS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 139
6.4.2.2 Gels 140
6.4.2.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels 140
TABLE 55 TOPICAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 140
6.4.2.3 Ointments 141
6.4.2.3.1 Ointments are widely used in analgesic indications 141
TABLE 56 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 141
6.4.2.4 Pastes 142
6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation 142
TABLE 57 TOPICAL PASTES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 142
6.4.2.5 Lotions 143
6.4.2.5.1 Easy administration of lotions to drive the demand among end users 143
TABLE 58 TOPICAL LOTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 143
6.4.3 SOLID FORMULATIONS 144
TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 144
TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 144
6.4.3.1 Suppositories 145
6.4.3.1.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug 145
TABLE 61 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 145
6.4.3.2 Powders 146
6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight 146
TABLE 62 TOPICAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 146
6.4.4 TRANSDERMAL PRODUCTS 147
TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 147
TABLE 64 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2019–2026 (USD BILLION) 148
6.4.4.1 Transdermal patches 148
6.4.4.1.1 Transdermal patches to prevent the premature metabolization of the drug through the liver 148
TABLE 65 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149
6.4.4.2 Transdermal gels 150
6.4.4.2.1 Transdermal gels to help in a faster release of drugs on the target site 150
TABLE 66 TRANSDERMAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 150
6.5 OCULAR DRUG DELIVERY 151
TABLE 67 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 151
TABLE 68 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 152
6.5.1 LIQUID FORMULATIONS 152
TABLE 69 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 153
TABLE 70 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 153
6.5.1.1 Eye drops 154
6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth 154
TABLE 71 COMMERCIALLY AVAILABLE EYE DROPS 154
TABLE 72 EYE DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 155
6.5.1.2 Liquid sprays 155
6.5.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops 155
TABLE 73 LIQUID SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 156
6.5.2 SEMI SOLID FORMULATIONS 156
TABLE 74 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 157
TABLE 75 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 157
6.5.2.1 Gels 158
6.5.2.1.1 The high viscosity of drugs, prolonged drug release, and the ease of drug administration are factors contributing to market growth 158
TABLE 76 OCULAR GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 158
6.5.2.2 Eye ointments 159
6.5.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug 159
TABLE 77 EYE OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 160
6.5.3 OCULAR DEVICES 160
TABLE 78 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 161
TABLE 79 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2019–2026 (USD BILLION) 161
6.5.3.1 Drug-coated contact lenses 162
6.5.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses 162
TABLE 80 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 162
6.5.3.2 Ocular inserts 163
6.5.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye 163
TABLE 81 OCULAR INSERTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 163
6.6 PULMONARY DRUG DELIVERY 164
TABLE 82 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 164
TABLE 83 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 165
6.6.1 METERED-DOSE INHALERS 165
6.6.1.1 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath 165
TABLE 84 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 166
6.6.2 DRY POWDER INHALERS 166
6.6.2.1 Dry powder inhaler formulations are chemically more stable than their counterparts 166
TABLE 85 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2019–2026 (USD BILLION) 167
6.6.3 NEBULIZERS 167
TABLE 86 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 168
TABLE 87 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2019–2026 (USD BILLION) 168
6.6.3.1 Jet nebulizers 169
6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market 169
TABLE 88 JET NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 169
6.6.3.2 Ultrasonic nebulizers 170
6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle 170
TABLE 89 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 170
6.6.3.3 Soft mist nebulizers 171
6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD 171
TABLE 90 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 171
6.7 NASAL DRUG DELIVERY 172
TABLE 91 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 172
TABLE 92 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 173

6.7.1 NASAL DROPS 173
6.7.1.1 Nasal drops are considered more efficient than nasal sprays 173
TABLE 93 NASAL DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 174
6.7.2 NASAL SPRAYS 174
6.7.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing 174
TABLE 94 NASAL SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 175
6.7.3 NASAL POWDERS 175
6.7.3.1 The absence of preservatives and superior stability of formulations are some of the advantages associated with nasal powders 175
TABLE 95 NASAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 176
6.7.4 NASAL GELS 176
6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients 176
TABLE 96 NASAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 177
6.8 TRANSMUCOSAL DRUG DELIVERY 177
TABLE 97 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 178
TABLE 98 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 179
6.8.1 ORAL FORMULATIONS 179
TABLE 99 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 180
TABLE 100 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 180
6.8.1.1 Buccal drug delivery 181
6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies 181
TABLE 101 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 181
6.8.1.2 Sublingual drug delivery 182
6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route 182
TABLE 102 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 183
6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES 183
TABLE 103 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 184
TABLE 104 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 184
6.8.2.1 Rectal transmucosal drug delivery 185
6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature 185
TABLE 105 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 185
6.8.2.2 Vaginal transmucosal drug delivery 186
6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration 186
TABLE 106 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 186
6.9 IMPLANTABLE DRUG DELIVERY 187
TABLE 107 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 187
TABLE 108 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 188
6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY 188
6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionizing radiation 188
TABLE 109 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 189
6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY 189
6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants 189
TABLE 110 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 190

7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION 191
7.1 INTRODUCTION 192
7.2 COVID-19 IMPACT, BY APPLICATION 192
TABLE 111 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 193
7.3 INFECTIOUS DISEASES 193
7.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH 193
TABLE 112 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 195
7.4 CANCER 195
7.4.1 CANCER TO FORM A KEY THERAPEUTIC APPLICATION SEGMENT FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 195
FIGURE 29 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020) 196
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS) 196
TABLE 113 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 197
TABLE 114 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION) 198
7.5 CARDIOVASCULAR DISEASES 198
7.5.1 INCREASING PREVALENCE OF CVDS AND INCREASING INNOVATION IN THE PHARMACEUTICAL DRUG DELIVERY SEGMENT TO PROPEL MARKET GROWTH 198
TABLE 115 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 199
TABLE 116 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 200

7.6 DIABETES 200
7.6.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 200
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS) 201
TABLE 117 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD BILLION) 202
7.7 RESPIRATORY DISEASES 202
7.7.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE THE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY 202
TABLE 118 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020) 203
TABLE 119 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 204
7.8 CENTRAL NERVOUS SYSTEM DISORDERS 204
7.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS 204
TABLE 120 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION) 206
7.9 AUTOIMMUNE DISEASES 206
7.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD 206
TABLE 121 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 207
7.10 OTHER APPLICATIONS 208
7.10.1 OPHTHALMIC DISORDERS 208
7.10.2 ENDOCRINE DISORDERS 208
TABLE 122 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 209

8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 210
8.1 INTRODUCTION 211
TABLE 123 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 211
8.2 HOSPITALS 212
8.2.1 HOSPITALS DOMINATE THE GLOBAL MARKET WITH THE HIGH VOLUME OF PRESCRIPTIONS FOR INPATIENT AND OUTPATIENT VISITS 212
TABLE 124 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD BILLION) 213
8.3 AMBULATORY SURGERY CENTERS/CLINICS 214
8.3.1 INCREASING PREFERENCE FOR AMBULATORY SURGERY CENTERS TO RESULT IN A SIGNIFICANT RISE IN DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES 214
TABLE 125 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD BILLION) 215

8.4 HOME CARE SETTINGS 215
8.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 215
TABLE 126 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD BILLION) 216
8.5 DIAGNOSTIC CENTERS 216
8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 216
TABLE 127 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD BILLION) 217
8.6 OTHER FACILITIES OF USE 217
TABLE 128 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2019–2026 (USD BILLION) 218

9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION 219
9.1 INTRODUCTION 220
FIGURE 32 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT (2020) 220
TABLE 129 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2019–2026 (USD BILLION) 221
9.2 NORTH AMERICA 221
FIGURE 33 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 223
TABLE 130 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 224
TABLE 131 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 224
TABLE 132 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 225
TABLE 133 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225
TABLE 134 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 225
TABLE 135 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 226
TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 226
TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 226
TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 227
TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 227
TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 227
TABLE 141 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 228
TABLE 142 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228
TABLE 143 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 228
TABLE 144 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 229
TABLE 145 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 229
TABLE 146 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 229
TABLE 147 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 148 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 149 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 230
TABLE 150 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 151 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 152 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 231
TABLE 153 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 232
TABLE 154 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 232
TABLE 155 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 232
TABLE 156 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 233
TABLE 157 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 233
TABLE 158 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 234
9.2.1 US 234
9.2.1.1 The US to dominate the North American pharmaceutical drug delivery market 234
TABLE 159 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 235
TABLE 160 US: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 235
TABLE 161 US: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236
TABLE 162 US: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 236
TABLE 163 US: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 236
TABLE 165 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 237
TABLE 166 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES,
BY MATERIAL, 2019–2026 (USD BILLION) 237
TABLE 167 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 237
TABLE 168 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 238
TABLE 169 US: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 238
TABLE 170 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 238
TABLE 171 US: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239
TABLE 172 US: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 239
TABLE 173 US: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 239
TABLE 174 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240
TABLE 175 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 240
TABLE 176 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 240
TABLE 177 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241
TABLE 178 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 241
TABLE 179 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 241
TABLE 180 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 242
TABLE 181 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 242
TABLE 182 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 242
TABLE 183 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 184 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 185 US: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 243
TABLE 186 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 244
TABLE 187 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 244
9.2.2 CANADA 245
9.2.2.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada 245
TABLE 188 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 246
TABLE 189 CANADA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 246
TABLE 190 CANADA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 247
TABLE 191 CANADA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 247
TABLE 192 CANADA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 247
TABLE 193 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 248
TABLE 194 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 248
TABLE 195 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 248
TABLE 196 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 249
TABLE 197 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 249
TABLE 198 CANADA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 249
TABLE 199 CANADA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 250
TABLE 200 CANADA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 250
TABLE 201 CANADA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 250
TABLE 202 CANADA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 251
TABLE 203 CANADA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 251
TABLE 204 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 251
TABLE 205 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 252
TABLE 206 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 252
TABLE 207 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 252
TABLE 208 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 253
TABLE 209 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 253
TABLE 210 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 253
TABLE 211 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 254
TABLE 212 CANADA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 254
TABLE 213 CANADA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 254
TABLE 214 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 255
TABLE 215 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 255
9.3 EUROPE 256
TABLE 216 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 256
TABLE 217 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 257
TABLE 218 EUROPE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 257
TABLE 219 EUROPE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 258
TABLE 220 EUROPE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 258
TABLE 221 EUROPE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 258
TABLE 222 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 259
TABLE 223 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 259
TABLE 224 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 259
TABLE 225 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 260
TABLE 226 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 260
TABLE 227 EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 260
TABLE 228 EUROPE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 261
TABLE 229 EUROPE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 261
TABLE 230 EUROPE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 261
TABLE 231 EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 262
TABLE 232 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 262
TABLE 233 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 262
TABLE 234 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 263
TABLE 235 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 263
TABLE 236 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 263
TABLE 237 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 264
TABLE 238 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 264
TABLE 239 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 264
TABLE 240 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 265
TABLE 241 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 265
TABLE 242 EUROPE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 265
TABLE 243 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 266
TABLE 244 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 266
9.3.1 GERMANY 267
9.3.1.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive the market in Germany 267
TABLE 245 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 268
TABLE 246 GERMANY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 268
TABLE 247 GERMANY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 269
TABLE 248 GERMANY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 269
TABLE 249 GERMANY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 269
TABLE 250 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 270
TABLE 251 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 270
TABLE 252 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 270
TABLE 253 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 271
TABLE 254 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 271
TABLE 255 GERMANY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 271
TABLE 256 GERMANY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 272
TABLE 257 GERMANY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 272
TABLE 258 GERMANY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 272
TABLE 259 GERMANY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 273
TABLE 260 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 273
TABLE 261 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 273
TABLE 262 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 274
TABLE 263 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 274
TABLE 264 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 274
TABLE 265 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 275
TABLE 266 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 275
TABLE 267 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 275
TABLE 268 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 276
TABLE 269 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 276
TABLE 270 GERMANY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 276
TABLE 271 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 277
TABLE 272 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 277
9.3.2 FRANCE 278
9.3.2.1 Presence of leading pharmaceutical companies along with the increasing prevalence of chronic diseases to drive market growth in France 278
TABLE 273 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 279
TABLE 274 FRANCE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 279
TABLE 275 FRANCE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 280
TABLE 276 FRANCE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 280
TABLE 277 FRANCE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 280
TABLE 278 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 281
TABLE 279 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 281
TABLE 280 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 281
TABLE 281 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 282
TABLE 282 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD MILLION) 282
TABLE 283 FRANCE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 282
TABLE 284 FRANCE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 283
TABLE 285 FRANCE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 283
TABLE 286 FRANCE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 283
TABLE 287 FRANCE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 284
TABLE 288 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 284
TABLE 289 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 284
TABLE 290 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 285
TABLE 291 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 285
TABLE 292 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 285
TABLE 293 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 286
TABLE 294 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 286
TABLE 295 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 286
TABLE 296 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 287
TABLE 297 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 287
TABLE 298 FRANCE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 287
TABLE 299 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 288
TABLE 300 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 288
9.3.3 ITALY 289
9.3.3.1 Increasing focus on clinical research and the growing popularity of branded drugs to drive the demand for pharmaceutical drug manufacturing 289
TABLE 301 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 290
TABLE 302 ITALY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 290
TABLE 303 ITALY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 291
TABLE 304 ITALY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 291
TABLE 305 ITALY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 291
TABLE 306 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 292
TABLE 307 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 292
TABLE 308 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 292
TABLE 309 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 293
TABLE 310 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 293
TABLE 311 ITALY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 293
TABLE 312 ITALY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 294
TABLE 313 ITALY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 294
TABLE 314 ITALY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 294
TABLE 315 ITALY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 295
TABLE 316 ITALY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 295
TABLE 317 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 295
TABLE 318 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 296
TABLE 319 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 296
TABLE 320 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 296
TABLE 321 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 297
TABLE 322 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 297
TABLE 323 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 297
TABLE 324 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 298
TABLE 325 ITALY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 298
TABLE 326 ITALY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 298
TABLE 327 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 299
TABLE 328 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 299
9.3.4 UK 300
9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for pharmaceutical drug delivery in the UK 300
TABLE 329 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 301
TABLE 330 UK: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 301
TABLE 331 UK: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 302
TABLE 332 UK: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 302
TABLE 333 UK: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 302
TABLE 334 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 303
TABLE 335 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 303
TABLE 336 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 303
TABLE 337 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 304
TABLE 338 UK: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 304
TABLE 339 UK: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 304
TABLE 340 UK: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 305
TABLE 341 UK: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 305
TABLE 342 UK: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 305
TABLE 343 UK: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 306
TABLE 344 UK: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 306
TABLE 345 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 306
TABLE 346 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 307
TABLE 347 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 307
TABLE 348 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 307
TABLE 349 UK: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 308
TABLE 350 UK: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 308
TABLE 351 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 308
TABLE 352 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 309
TABLE 353 UK: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 309
TABLE 354 UK: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 309
TABLE 355 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 310
TABLE 356 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 310

9.3.5 SPAIN 311
9.3.5.1 Increase in biologics production to support market growth 311
TABLE 357 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 311
TABLE 358 SPAIN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 312
TABLE 359 SPAIN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 312
TABLE 360 SPAIN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 312
TABLE 361 SPAIN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 313
TABLE 362 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 313
TABLE 363 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 313
TABLE 364 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 314
TABLE 365 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 314
TABLE 366 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 314
TABLE 367 SPAIN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 315
TABLE 368 SPAIN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 315
TABLE 369 SPAIN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 315
TABLE 370 SPAIN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 316
TABLE 371 SPAIN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 316
TABLE 372 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 316
TABLE 373 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 317
TABLE 374 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 317
TABLE 375 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 317
TABLE 376 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION) 318
TABLE 377 SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MLLION) 318
TABLE 378 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 318
TABLE 379 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 319
TABLE 380 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 319
TABLE 381 SPAIN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 319
TABLE 382 SPAIN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 320
TABLE 383 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 320
TABLE 384 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 321
9.3.6 REST OF EUROPE 321
TABLE 385 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 322
TABLE 386 ROE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 322
TABLE 387 ROE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 323
TABLE 388 ROE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 323
TABLE 389 ROE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 323
TABLE 390 ROE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 324
TABLE 391 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 324
TABLE 392 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 324
TABLE 393 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 325
TABLE 394 ROE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 325
TABLE 395 ROE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 325
TABLE 396 ROE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 326
TABLE 397 ROE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 326
TABLE 398 ROE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 326
TABLE 399 ROE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 327
TABLE 400 ROE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 327
TABLE 401 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 327
TABLE 402 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 328
TABLE 403 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 328
TABLE 404 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 328
TABLE 405 ROE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 329
TABLE 406 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 329
TABLE 407 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 329
TABLE 408 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 330
TABLE 409 ROE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 330
TABLE 410 ROE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 330
TABLE 411 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 331
TABLE 412 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 331
9.4 ASIA PACIFIC 332
FIGURE 34 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT 333
TABLE 413 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 334
TABLE 414 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 334
TABLE 415 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 335
TABLE 416 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 335
TABLE 417 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 335
TABLE 418 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 336
TABLE 419 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 336
TABLE 420 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 336
TABLE 421 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 337
TABLE 422 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 337
TABLE 423 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 337
TABLE 424 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 338
TABLE 425 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 338
TABLE 426 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 338
TABLE 427 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 339
TABLE 428 ASIA PACIFIC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 339
TABLE 429 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 339
TABLE 430 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 340
TABLE 431 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 340
TABLE 432 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 340
TABLE 433 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 341
TABLE 434 ASIA PACIFIC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 341
TABLE 435 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 341
TABLE 436 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 342
TABLE 437 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 342
TABLE 438 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 342
TABLE 439 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 343
TABLE 440 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 343
TABLE 441 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 344
9.4.1 CHINA 344
9.4.1.1 China had the largest diabetic population in the world in 2020 344
TABLE 442 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 345
TABLE 443 CHINA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 346
TABLE 444 CHINA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 346
TABLE 445 CHINA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 346
TABLE 446 CHINA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 347
TABLE 447 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 347
TABLE 448 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 347
TABLE 449 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 348
TABLE 450 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 348
TABLE 451 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 348
TABLE 452 CHINA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 349
TABLE 453 CHINA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 349
TABLE 454 CHINA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 349
TABLE 455 CHINA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 350
TABLE 456 CHINA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 350
TABLE 457 CHINA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 350
TABLE 458 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 351
TABLE 459 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 351
TABLE 460 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 351
TABLE 461 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 352
TABLE 462 CHINA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 352
TABLE 463 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 352
TABLE 464 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 353
TABLE 465 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 353
TABLE 466 CHINA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 353
TABLE 467 CHINA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 354
TABLE 468 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 354
TABLE 469 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 355
9.4.2 JAPAN 355
9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan 355
TABLE 470 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 356
TABLE 471 JAPAN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 357
TABLE 472 JAPAN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 357
TABLE 473 JAPAN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 357
TABLE 474 JAPAN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 358
TABLE 475 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 358
TABLE 476 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 358
TABLE 477 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 359
TABLE 478 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 359
TABLE 479 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 359
TABLE 480 JAPAN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 360
TABLE 481 JAPAN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 360
TABLE 482 JAPAN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 360
TABLE 483 JAPAN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 361
TABLE 484 JAPAN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 361
TABLE 485 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 361
TABLE 486 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 362
TABLE 487 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 362
TABLE 488 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 362
TABLE 489 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 363
TABLE 490 JAPAN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 363
TABLE 491 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 363
TABLE 492 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 364
TABLE 493 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 364
TABLE 494 JAPAN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 364
TABLE 495 JAPAN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 365
TABLE 496 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 365
TABLE 497 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 366

9.4.3 INDIA 366
9.4.3.1 Growing generic demand and rising government initiatives to drive market growth in India 366
TABLE 498 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 367
TABLE 499 INDIA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 367
TABLE 500 INDIA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 368
TABLE 501 INDIA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 368
TABLE 502 INDIA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 368
TABLE 503 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 369
TABLE 504 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 369
TABLE 505 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 369
TABLE 506 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 370
TABLE 507 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 370
TABLE 508 INDIA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 370
TABLE 509 INDIA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 371
TABLE 510 INDIA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 371
TABLE 511 INDIA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 371
TABLE 512 INDIA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 372
TABLE 513 INDIA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 372
TABLE 514 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 372
TABLE 515 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 373
TABLE 516 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 373
TABLE 517 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION) 373
TABLE 518 INDIA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 374
TABLE 519 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 374
TABLE 520 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 374
TABLE 521 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 375
TABLE 522 INDIA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 375
TABLE 523 INDIA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 375
TABLE 524 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 376
TABLE 525 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 376
9.4.4 REST OF ASIA PACIFIC 377
TABLE 526 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 378
TABLE 527 ROAPAC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 378
TABLE 528 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 379
TABLE 529 ROAPAC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 379
TABLE 530 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 379
TABLE 531 ROAPAC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 380
TABLE 532 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 380
TABLE 533 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 380
TABLE 534 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 381
TABLE 535 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 381
TABLE 536 ROAPAC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 381
TABLE 537 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 382
TABLE 538 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 382
TABLE 539 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 382
TABLE 540 ROAPAC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 383
TABLE 541 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 383
TABLE 542 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 383
TABLE 543 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 384
TABLE 544 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 384
TABLE 545 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 384
TABLE 546 ROAPAC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 385
TABLE 547 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 385
TABLE 548 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 385
TABLE 549 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 386
TABLE 550 ROAPAC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 386
TABLE 551 ROAPAC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 386
TABLE 552 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 387
TABLE 553 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 387
9.5 LATIN AMERICA 388
9.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 388
TABLE 554 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 389
TABLE 555 LATIN AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 389
TABLE 556 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 390
TABLE 557 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 390
TABLE 558 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 390
TABLE 559 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 391
TABLE 560 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 391
TABLE 561 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 391
TABLE 562 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 392
TABLE 563 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 392
TABLE 564 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 392
TABLE 565 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 393
TABLE 566 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 393
TABLE 567 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 393
TABLE 568 LATIN AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION) 394
TABLE 569 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 394
TABLE 570 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 394
TABLE 571 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 395
TABLE 572 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 395
TABLE 573 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION) 395
TABLE 574 LATIN AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 396
TABLE 575 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 396
TABLE 576 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 396
TABLE 577 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 397
TABLE 578 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 397
TABLE 579 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 397
TABLE 580 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 398
TABLE 581 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 398
9.6 MIDDLE EAST & AFRICA 399
9.6.1 GOVERNMENT SUPPORT BOOSTING LOCAL PRODUCTION TO OFFER GROWTH OPPORTUNITIES FOR PHARMACEUTICAL MANUFACTURERS 399
TABLE 582 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION) 400
TABLE 583 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 400
TABLE 584 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 401
TABLE 585 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 401
TABLE 586 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION) 401
TABLE 587 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 402
TABLE 588 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION) 402
TABLE 589 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION) 402
TABLE 590 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION) 403
TABLE 591 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION) 403
TABLE 592 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 403
TABLE 593 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 404
TABLE 594 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 404
TABLE 595 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION) 404
TABLE 596 MIDDLE EAST & AFRICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD MILLION) 405
TABLE 597 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 405
TABLE 598 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 405
TABLE 599 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 406
TABLE 600 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION) 406
TABLE 601 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION) 406
TABLE 602 MIDDLE EAST & AFRICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 407
TABLE 603 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION) 407
TABLE 604 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION) 407
TABLE 605 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION) 408
TABLE 606 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION) 408
TABLE 607 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION) 408
TABLE 608 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 409
TABLE 609 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION) 409

10 COMPETITIVE LANDSCAPE 410
10.1 OVERVIEW 410
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 410
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET 411
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 412
10.4 MARKET SHARE ANALYSIS 413
FIGURE 36 PHARMACEUTICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2020 413
TABLE 610 PHARMACEUTICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION 414
10.5 COMPETITIVE BENCHMARKING 414
TABLE 611 FOOTPRINT OF COMPANIES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET 414
TABLE 612 COMPANY PRODUCT OFFERING FOOTPRINT (20 COMPANIES) 415
TABLE 613 COMPANY APPLICATION FOOTPRINT (20 COMPANIES) 416
TABLE 614 COMPANY FACILITY OF USE FOOTPRINT (20 COMPANIES) 417
TABLE 615 COMPANY REGION FOOTPRINT (20 COMPANIES) 418
10.6 COMPETITIVE LEADERSHIP MAPPING 419
10.6.1 STARS 419
10.6.2 EMERGING LEADERS 419
10.6.3 PERVASIVE PLAYERS 419
10.6.4 PARTICIPANTS 420
FIGURE 37 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 420
10.7 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS 420
10.7.1 PROGRESSIVE COMPANIES 421
10.7.2 DYNAMIC COMPANIES 421
10.7.3 STARTING BLOCKS 421
10.7.4 RESPONSIVE COMPANIES 421
FIGURE 38 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020) 422
10.8 COMPETITIVE SCENARIO 422
10.8.1 PRODUCT LAUNCHES & APPROVALS 423
10.8.2 DEALS 424
10.8.3 OTHER DEVELOPMENTS 425

11 COMPANY PROFILES 426
11.1 KEY PLAYERS 426
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
11.1.1 JOHNSON & JOHNSON 426
TABLE 619 JOHNSON & JOHNSON: BUSINESS OVERVIEW 426
FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020) 427
11.1.2 NOVARTIS INTERNATIONAL AG 440
TABLE 620 NOVARTIS INTERNATIONAL AG: BUSINESS OVERVIEW 440
FIGURE 40 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2020) 441
11.1.3 F. HOFFMANN-LA ROCHE AG 449
TABLE 621 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 449
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020) 450
11.1.4 PFIZER INC. 455
TABLE 622 PFIZER INC. : BUSINESS OVERVIEW 455
FIGURE 42 PFIZER INC.: COMPANY SNAPSHOT (2020) 456
11.1.5 BECTON, DICKINSON AND COMPANY 468
TABLE 623 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 468
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 469
11.1.6 GLAXOSMITHKLINE PLC 474
TABLE 624 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW 474
FIGURE 44 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020) 475
11.1.7 MERCK & CO., INC. 483
TABLE 625 MERCK & CO., INC.: BUSINESS OVERVIEW 483
FIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2020) 484
11.1.8 SANOFI 491
TABLE 626 SANOFI: BUSINESS OVERVIEW 491
FIGURE 46 SANOFI: COMPANY SNAPSHOT (2020) 492
11.1.9 BAYER AG 498
TABLE 627 BAYER AG: BUSINESS OVERVIEW 498
FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2020) 499
11.1.10 3M 505
TABLE 628 3M: BUSINESS OVERVIEW 505
FIGURE 48 3M: COMPANY SNAPSHOT (2020) 506
11.1.11 ANTARES PHARMA, INC. 508
TABLE 629 ANTARES PHARMA, INC.: BUSINESS OVERVIEW 508
11.1.12 AMGEN, INC. 510
TABLE 630 AMGEN, INC. : BUSINESS OVERVIEW 510
FIGURE 49 AMGEN, INC. : COMPANY SNAPSHOT (2020) 510
11.1.13 ABBVIE INC. 514
TABLE 631 ABBVIE INC.: BUSINESS OVERVIEW 514
11.1.14 GENMAB A/S 517
TABLE 632 GENMAB A/S : BUSINESS OVERVIEW 517
11.1.15 GILEAD SCIENCES, INC. 519
TABLE 633 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW 519
11.1.16 BOEHRINGER INGELHEIM 523
TABLE 634 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW 523
FIGURE 50 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020) 524
11.1.17 ASTRAZENECA PLC 527
TABLE 635 ASTRAZENECA PLC: BUSINESS OVERVIEW 527
FIGURE 51 ASTRAZENECA: COMPANY SNAPSHOT (2020) 528
11.1.18 ELI LILLY AND COMPANY 531
TABLE 636 ELI LILLY AND COMPANY: BUSINESS OVERVIEW 531
FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020) 532
11.1.19 TEVA PHARMACEUTICAL INDUSTRIES LTD. 535
TABLE 637 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW 535
11.1.20 BRISTOL-MYERS SQUIBB 538
TABLE 638 BRISTOL-MYERS SQUIBB: BUSINESS OVERVIEW 538
*Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies.

11.2 OTHER PLAYERS 540
11.2.1 GERRESHEIMER AG 540
11.2.2 BOSTON SCIENTIFIC CORPORATION 541
11.2.3 NIMBUS THERAPEUTICS 542
11.2.4 KITE PHARMA 543
11.2.5 IDEAYA BIOSCIENCES, INC. 544

12 APPENDIX 545
12.1 INSIGHTS FROM INDUSTRY EXPERTS 545
12.2 DISCUSSION GUIDE 546
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 552
12.4 AVAILABLE CUSTOMIZATIONS 554
12.5 RELATED REPORTS 554
12.6 AUTHOR DETAILS 555


お問合せフォーム

    ※レポートのタイトルは自動で入ります。

    お名前(必須)

    会社名(必須)

    部署名

    メールアドレス(必須)

    電話番号

    当ウェブサイトを知った経由を教えてください。

    お問合せ区分(必須)

    お問合せ内容(必須)

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com